Global Acne Drugs Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Acne Drugs Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Acne drugs refer to the medications used for treating a dermatological infection characterized by the inflammation in the hair follicles on skin. It is usually caused by hormonal imbalance, oily skin, accumulation of dead skin cells, bacteria, stress, inadequate intake of water and excessive consumption of sugars, salts or carbohydrates. Some of the commonly used acne drugs include topical medications, such as retinoids, salicylic and azelaic acid-based ointments and dapsonebased gels, along with antibiotics, anti-androgen agents and isotretinoin. These drugs minimize the levels of oil production in the body, speed up skin cell turnover, control acne breakouts, reduce scarring and damage to the skin and prevent inflammation.

Market Overview:

The latest research study on the global Acne Drugs market finds that the global Acne Drugs market reached a value of USD 5709.0 million in 2022. It’s expected that the market will achieve USD 6981.56 million by 2028, exhibiting a CAGR of 3.41% during the forecast period.

Influence of COVID-19 Outbreak on Acne Drugs Industry Development

In the context of COVID-19, various government agencies, research institutes, and many biotech and pharmaceutical companies are working to develop effective and rapid technologies to rapidly diagnose COVID-19 and develop vaccines/new treatments to overcome the current situation. The manufacturing sectors of all healthcare companies are affected, and transportation in all developed and emerging markets is severely affected. The acne treatment market is expected to experience some indirect and direct negative impacts over the forecast period. In the case of acne treatments, the supply chain of important prescription products is expected to meet the shortage of treatment products in various countries. The economic slowdown is also expected to increase the complexity of supply chain work at home and abroad. Because of this situation, clinical trials of approved drugs for other indications and new drugs are slowing down. Furthermore, market players cannot place more burden on clinical trials and manufacturing of approved drugs, as healthcare institutions have recently been overwhelmed by the COVID-19 crisis.

The number of patient visits/consultations to dermatologists has decreased significantly due to the lockdown and social distancing rules imposed by the government to control the spread of the coronavirus. The market is expected to witness a decline in its growth rate as acne treatment requires dermatologist consultation for medication and treatment. A study conducted by the American Academy of Dermatology with American dermatologists reported a nearly 43% drop in weekly patient consultations during the lockdown compared to pre-COVID levels. Dermatologyrelated consultations declined much more than specialties such as oncology due to the lack of urgency by patients and physicians to seek dermatology

Acne Drugs Market Challenges

Side effects associated with acne products challenge the market. The US Food and Drug Administration (FDA) has cautioned that the use of certain over-the-counter (OTC) acne medications may cause potentially lifethreatening allergic reactions or severe irritation. For example, in 2014, the FDA issued certain safety alerts about the use of benzoyl peroxide for this treatment. Some medications used in acne treatment are reported to have severe adverse effects on health. For instance, isotretinoin, an oral drug used in acne treatment has been associated with several ill effects, especially for pregnant women. This drug can cause severe birth defects in the developing fetus of a pregnant woman. Other products constituting isotretinoin can potentially cause mental health problems along with adverse effects such as itching, muscle aches, nose bleeding, poor night vision and changes in liver function among others.

The side effects of acne drugs are challenging for the market, and reducing the scope and extent of side effects is an important challenge for companies.

Region Overview:

From 2023-2028, North America is estimated to witness robust growth prospects.

Company Overview:

Galderma Holding SA is one of the major players operating in the Acne Drugs market, holding a share of 28.34% in 2021.

Galderma S.A. is a Swiss pharmaceutical company specializing in dermatological treatments and skin care products.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Segmentation Overview:

Among different product types, Retinoids segment is anticipated to contribute the largest market share in 2028.

Application Overview:

By application, the Offline segment occupied the biggest share from 2018 to 2022.

Key Companies in the global Acne Drugs market covered in Chapter 3:

Johnson & Johnson
Cipher Pharmaceuticals Inc.
Almirall SA.
Bausch Health Companies Inc.
Galderma Holding SA
Sun Pharmaceutical Industries Limited
Pfizer Inc.
Teva Pharmaceutical Industries Ltd
Reckitt Benckiser Group Plc

In Chapter 4 and Chapter 14.2, on the basis of types, the Acne Drugs market from 2018 to 2029 is primarily split into:

Retinoids
Antibiotics
Hormonal Agents
Combination Drugs
Others

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Acne Drugs market from 2018 to 2029 covers:

Online
Offline

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)